U.S. FDA Head Asks Congress For Import-Drug Inspection Funds
This article was originally published in PharmAsia News
The head of the U.S. FDA broke with the administration to tell Congress his agency needs another $275 million if it is to inspect imported drugs and medical devices. Commissioner Andrew von Eschenbach wrote to a key senator to cite the need for offices in other countries and increased inspections. The funding request is beyond the administration's budget request submitted earlier this year. Since then, FDA has been under pressure to ensure the safety of drug imports in the wake of the tainted heparin scare in China. (Click here for more
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.